Nanomaterial - human health risk assessment -

Slides:



Advertisements
Similar presentations
Chemicals and Women- So what is the problem? WOMEN FOR A TOXIC-FREE FUTURE Polish Women´s Seminar & Workshop Monday 6th of December 2004, Warsaw Daniela.
Advertisements

Andrej Kobe EP Brussels, 21 November 2011
Workplace exposure to nanoparticles. Workplace exposure to nanoparticles Aims  To provide the Risk Observatory target audience with a comprehensive picture.
Canada/Australia Issues being faced in the regulation of nano-materials Deborah Willcocks – Department of Health and Ageing, Government of Australia Anne-Marie.
© 2004 Prof Roland Clift NANOTECHNOLOGY Professor Roland Clift, Centre for Environmental Strategy, University of Surrey, GUILDFORD, Surrey GU2 7XH, UK.
Lab Safety Nanoparticles. Background The ASTM Committee on Nanotechnology has defined a nanoparticle as a particle with lengths in two or three dimensions.
Nanotechnology Work Health & Safety Food & Grocery Nanotechnology Forum 26 February 2013 Howard Morris (Safe Work Australia) 1.
Chemicals Inventory Management as a Tool to Check Compliance with Restricted Substances Regulations Ursula Schumacher.
Toxics Use Reduction Institute Chemicals Policy in Europe: New Directions Rachel Massey Policy Analyst April 2006.
ECVAM Key Area Sensitisation: Overview on Activities Silvia Casati, Chantra Eskes.
"Informational needs and the regulatory frame for consumer applications: The EU Commission's view" Philippe Martin European Commission Directorate-General.
Copyright 2002 Marc Rigas Issues in Exposure Assessment Marc L. Rigas, Ph.D. National Exposure Research Laboratory, U.S. Environmental Protection Agency.
1 REACh Registration, Evaluation and Authorization of Chemicals and Restriction! Ohio Valley SOT Wednesday, August 26, 2009 REACh: The New Toxicology Frontier.
Nanotechnology and Manufactured Nanomaterials: Environment, Health and Safety Issues REINER ARNDT, UNITAR.
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
Nano-Safety: Some Future Perspectives Conference on Nano-Safety April, Slovenia, Ljubljana Bjorn G. Hansen dHoU Chemicals, DG ENV, European Commission.
Nanomaterials: Potential impact on human health Paul J.A. Borm Paris- OECD- june 7 th 2005.
Accident Prevention Manual for Business & Industry: Engineering & Technology 13th edition National Safety Council Compiled by Dr. S.D. Allen Iske, Associate.
SSSG 2007 Global Harmonization System. What is GHS ? GHS is an international system designed to standardize the communication of hazardous substances.
The Approach of OECD to Nanosafety Peter Kearns Head, Nanosafety Team OECD Environment Directorate 1.
International Initiatives and the U.S. HPV Challenge Program Ken Geiser, PhD Lowell Center for Sustainable Production University of Massachusetts Lowell.
TRAINING FOR THE HEALTH SECTOR
Presentation 3: Are nanomaterials a worker health and safety risk?
Oregon State University Nanoparticles A Public Health Review 1 Joe Fisher H 546 – Industrial Hygiene Oregon State University 30 May 2008.
OECD Work on the Safety of Manufactured Nanomaterials Environment, Health and Safety Division Environment Directorate OECD October
Nanoparticles in the environment – how small is the risk? Anders Baun Nanna Hartmann Khara Grieger Michael Andersen Steffen Foss Hansen.
The Swiss Action Plan on Synthetic Nanomaterials: State of implementation Georg Karlaganis Regional Nano Workshop for Asia Pacific Bangkok Thailand 10.
Presentation 4: How can I know if nanomaterials are used in my workplace?
Material Safety Data Sheets Interpreting and Understanding Information on a MSDS.
REACH and CLP What formulators need to know. Purpose of this presentation This presentation, with notes, was prepared by ECHA, the European Chemicals.
Risk Assessment - Scientific Challenges A Perspective from the NanoSafety Project Team Jutta Jahnel.
EU Regulation 1907/2006 on the Registration Evaluation and Authorisation of CHemicals REACH Lunch & Learn Beach Ballroom, Aberdeen 29 th August 2007 R.
SAFETY PRECAUTIONS & TOXICITY RESEARCH NANOTECHNOLOGY.
New or increasing occupational exposure to chemical and biological agents Gérard Lasfargues Deputy Director General, Anses.
Nanomaterials classification and labelling – status of work undertaken in GHS (Globally Harmonized System of Classification and Labelling of Chemicals)
1 Risk Governance of Manufactured Nanoparticles, Joint Workshop EP STOA Panel – European Commission, Brussels, 21 November 2011 Interfaces between Science.
Nano-materials: Environmental and Health Impacts Chem Eng Progress: 104 (12), , 2008.
REACH, 12 Nov Supply chain communication Tatjana Humar –Jurič, M.Sc. Semira Hajrlahović Mehić, LL.M.
& H AS HEALTH AND SAFETY AUTHORITY REACH and Downstream Users Marie McCarthy REACH GI Inspector Health and Safety Authority.
What safety issues can you think of that need to be considered when introducing a new nano- product? Brainstorm.
FUNDAMENTALS OF OCCUPATIONAL TOXICOLOGY Vesa Riihimäki, MD, PhD, MSc Finnish Institute of Occupational Health.
Malaysia Update on “draft” proposal for the Environmentally Hazardous Substance (“EHS”) Notification and Registration Scheme.
Pollution and Human Health
Nanomaterials: Industrial Policy and Legislation Otto Linher DG Enterprise and Industry EESC, 9 September 2015 European Commission.
September 22, 2011 Office of Pollution Prevention and Toxics1.
ETUC Conference on REACH March 2005 Improving REACH ETUC proposals for REGISTRATION Werner SCHNEIDER DGB, Germany.
Can REACH become the New Global Model? Helsinki Chemicals Forum 20 May 2010 Jukka Malm, Director ECHA – Directorate of Assessment.
REACH: state of art and base definitions WERCS 2007 US User group Albany 27/06/2007 Dr. Erwin Annys Sr. Advisor Product & Innovation Policy.
September Fort Worth. 8th EU-US Joint Conference. Nano workgroup. Nanomaterial regulation in Europe Current workplace challenges Caroline Verdoot.
REACH: state of art and base definitions Dr. Erwin Annys Sr. Advisor Product & Innovation Policy WERCS 2007 EU User group Napoli 31/05/07.
NER: Identifying & Regulating Environmental Impacts of Nanotechnology PI: N. Swami; Co-PI: M. Gorman; Students (Degree Program): A. Wardak (Ph.D.), E.
Nanotechnologies – research needs from an EU policy and regulatory perspective NanoImpactNet, Lausanne, March 2010 Eva Hellsten, DG Environment,
NUATRC/TCEQ Air Toxics Workshop October Air Toxics Air Toxics: What We Know, What we Don’t Know, and What We Need to Know Human Health Effects –
The Ministry of Science, Technology and Innovation
Presentation for GBSO Networking Meeting REACH Regulation: Implications for businesses and the network.
Dr. Qasim Chaudhry The Food and Environment Research Agency
ASSE Conference: April 2006Industrial Hygiene Presentation Safety & Health Aspects of Nanotechnology.
Outcome of the Workshop on PFOA organised by the Commission 4 th of May 2010 Christine Wistuba, DG ENV, D3.
Purpose, Scope and Application of the GHS 1. The Globally Harmonized System of Classification and Labeling of Chemicals (GHS) is a rational and comprehensive.
Health and environmental impacts of nanoparticles: too early for a risk assessment framework? Prof Jim Bridges Emeritus Professor of Toxicology and Environmental.
Key elements of the concepts and approaches within the EU in the chemical sector Dr. Marcus Moreno-Horn TAIEX: Workshop, Yerevan 2-3 May 2011 Federal Office.
REACH & CLP Downstream user overview 1. Purpose of this presentation 2 This presentation, with notes, was prepared by.
Environmental and health issues: The case for a precautionary approach
Special Topics in Sustainable Nanochemistry
OECD work on manufactured nanomaterials
CCMI 9 September 2015 Public Hearing: Nanotechnology for a competitive chemical industry Social aspects: education, health and safety.
The proposed legislation
International Initiatives and the U.S. HPV Challenge Program
Presentation transcript:

Nanomaterial - human health risk assessment - Maria Wallén, toxicologist Reach Department Swedish Chemicals Agency (Kemikalieinspektionen) ____________________ Biomaterials Research Center, Gothenburg´s university Nov 13, 2008 www.kemi.se

Risk assessment in general Risk assessment and nanomaterials Definition of nanomaterial Issues to be considered in testing Legislation (REACH regulation) Nanomaterials in products Nanomaterials and human exposure Nanomaterials and human toxicity www.kemi.se

Human health risk assessment of chemicals Information on Exposure Phys/chem prop Toxicokinetics Effects Exposure assessment Exposed populations Exposure patterns Effects assessment Hazard identification Dose/response Exposure humans NOAEL animals Extrapolate experimental animal data to human situation Risk characterisation Exposure level / Effect level Risk management www.kemi.se

Human health risk assessment of nanomaterials Do we need to study nanomaterials differently compared to bulk chemicals? ? To be investigated! www.kemi.se

? Definition To be agreed! Size and shape Phys/chem properties 1 - 100 nanometer Phys/chem properties Large surface area per volume High reactivity Unique optical, electrical and magnetic properties Quantum effects Definition Intentionally formed Unintentionally formed Natural occurrance C60-fullerene ? To be agreed! SWCNT www.kemi.se

Issues to be considered in the risk assessment of nanomaterials (1) Exposure What are the relevant exposure metrics? Which data can be reliably collected? Analytical methodologies Effects of adsorption and aggregation Measurement strategies How should uncertainty of data be handled? www.kemi.se

Issues to be considered in the risk assessment of nanomaterials (2) Physical-chemical properties Aggregation (nanomaterial – nanomaterial interaction) Water solubility (nanomaterial held in a colloidal suspension) Shape Particle size distribution Specific surface area Surface chemistry www.kemi.se

Issues to be considered in the risk assessment of nanomaterials (3) Toxicokinetics – ADME (Absorption, Distribution, Metabolism, Elimination) The small particle size The shape and surface composition Aggregation may produce particles too large for absorption Interaction with molecules (proteins, lipids, salts, etc) in the biological environment leading e.g. to extensive tissue retention www.kemi.se

Issues to be considered in the risk assessment of nanomaterials (4) Effect endpoints Endpoints for testing Testing methods Sample preparation and dosimetry How to prepare the dosing material How to administer dosing material for tox. test Estimating dose Deposition of small materials? www.kemi.se

Exposure measurement and assessment OECD; Environment Directorate Working Party on Manufactured Nanomaterials (WPMN) Exposure measurement and assessment Investigate the possible use of current OECD test guidelines The role of alternative (non in vivo) test methods Risk assessment Safety testing of a representative set of manufactured nanomaterials (Sponsorship programme) www.kemi.se

Sponsorship Arrangement (OECD) To agree on a list of representative manufactured nanomaterials To develop a programme to test nanomaterials for human health and environmental safety www.kemi.se

Fullerenes (C60) JP, US --- CN SWCNTs CA, FR, DE, EC, CN, BIAC MWCNTs KR, BIAC Silver nanopart. KR, US AU, CA, DE AU, FR, EC, CN Iron nanopart. BIAC CA, US Carbon black DE, US Titanium dioxide DE CA, KR, ES, US, BIAC FR, CN Aluminium oxide Cerium oxide US, UK/BIAC(NIA) NL AU, DE, EC Zinc oxide UK/BIAC(NIA) AU, US, BIAC(CEFIC) AU, CA Silicon dioxide EC KR, BIAC(CEFIC) FR, EC Polystyrene KR Dendrimers ES US Nanoclays www.kemi.se

Legislation REACH Regulation (EC) No 1907/2006 Registation, Evaluation, Authorisation and Restriction of Chemicals ”REACH covers nanomaterials” (EU Commission) ? How do REACH apply to nanomaterials? To be considered! www.kemi.se

Issues to be considered in the REACH regulation and nanomaterials (examples) Obligation to register substances (Article 6, 7) Requirements for Safety Data Sheets (SDS) (Article 31) www.kemi.se

Obligation to register Any manufacturer or importer of a substance in quantities of one tonne or more per year shall submit a registration to the Agency. Any producer or importer of articles shall submit a registration to the Agency, if the substance is present in articles in quantities over one tonne per producer or importer per year….. www.kemi.se

Safety Data Sheets (SDS) The supplier of a substance shall provide the recipient of the substance with a safety data sheet if the substance meets the criteria for classification as dangerous (CMR); or the substance meets the criteria as persistent, bioaccumulative and toxic (PBT) …., or … an equivalent level of concern… (eg endocrine disrupters) www.kemi.se

Definition of nanomaterials Registration Chemical Safety Assessment Reach Competent Authorities subgroup on Nanomaterials (Reach CASG Nano) 2008-2012 Definition of nanomaterials Registration Chemical Safety Assessment Classification and labelling Testing methods inclusive alternative methods Safety data sheet (SDS) Authorisation and Restrictions Guidance www.kemi.se

www.kemi.se

Nanomaterials in products (examples) Electronics Househould products Clothes and textiles Sport items Automobiles Toys Hygiene articles Cosmetic products Food and food additives Pharmaceuticals www.kemi.se

Toxicity of nanomaterials Are nanomaterials toxic to human health? ? Knowledge is limited www.kemi.se

Exposure to humans - workers, consumers, man via the environment - Uptake via The lungs, the oral route, the skin, the olfactory nerve to the brain Passage via Blood-brain barrier Cell membranes into mitochondria and cell nucleus Localised to e.g. liver, spleen, lymph nodes, bone marrow, brain www.kemi.se

Effects on the lungs (1) Size high amount in the lungs of nanosized particles (TiO2 and Al2O3) compared to larger particles of the same substances  greater pulmonary inflammatory response (rats, mice) Shape high amount in the lungs of nanotubes (15-20 µm; SWCNT) compared to nanoparticles (quantum dots )  greater inflammatory response (often discussed in relation to asbestosis) (rats) www.kemi.se

Effects on the lungs (2) Surface area Nanoparticles with greater surface area were more cytotoxic than larger particles of equivalent mass (SiO2) (in vitro)  might explain pulmonary fibrosis www.kemi.se

Effects on the cardiovascular system Air pollution (nanosized particles) cause oxidative stress (rats; inhalation)  may lead to inflammation and myocardial cell injuries SWCNT respiratory exposure Induces oxidative stress and injuries in the vessel cells (mice; instilled in the lungs)  might lead to cardio-vascular diseases such as artherosclerosis Nanoparticles can modify blood clotting factors (mice; ip)  may lead to thrombosis www.kemi.se

Effects on the nervous system Positively charged nanoparticles (emulsifying wax) have toxic effect at the blood-brain barrier (rats; in situ brain perfusion)  disturbances of the BBB may lead to modified toxicity for nanosized material and chemicals in general www.kemi.se

Very limited knowledge Effects on the skin Effects on the reproductive system and foetuses Mutagenicity Cancer Effects on the immune system www.kemi.se

Finally, We need advise how to deal with nanomaterials in the legislation There are large uncertainties and limited knowledge on human health risks of nanomaterials There is a need to understand how to assess exposure to nanomaterials There is a need to establish adequate testing methods to evaluate the toxicity of nanomaterials There are problems to communicate possible risks caused by nanomaterials. www.kemi.se

KemI Report 3/08 Kemi Rapport 6/07 (sv) Nanotechnology High risks with small particles A compilation of available knowledge concerning risks for health and environment from nanotechnology, and proposals on measures for how to fill the identified knowledge gaps www.kemi.se Thank you for your attention! www.kemi.se